로딩 중…
지수 로딩 중…
BioAge Labs, Inc.
BIOA· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$10.78+19.25%
2026-08-03
Financials
Valuation Metrics
BioAge Labs, Inc.'s Market Cap is $479M. At end of 2025 it was $474M. Ranked #2871 of 3,111 in US market (top 92%), #1267 of 1,445 on NASDAQ (top 88%), #229 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 85%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $479M | US#2,871/3,111 Sec#229/269 |
| Revenue | $10M | US#2,928/3,111 Sec#181/269 |
| Net Income | $-90M | US—/3,111 Sec—/269 |
| Total Assets | $398M | US#2,841/3,111 Sec#189/269 |
| Net Assets | $379M | US#2,438/3,111 Sec#143/269 |
| Value | ||
| P/B | 1.26x | US#400/3,111 Sec#20/269 |
| P/S | 46.45x | US#2,873/3,111 Sec#165/269 |
| FCF Yield | -18.50% | US—/3,111 Sec—/269 |
| Profitability | ||
| ROE | -23.72% | US#2,568/3,111 Sec#113/269 |
| ROA | -22.62% | US#2,812/3,111 Sec#136/269 |
| Op. Margin | -985.93% | US#2,926/3,111 Sec#179/269 |
| Revenue Growth | 91.04% | US#167/3,111 Sec#37/269 |
| Financial Health | ||
| Debt Ratio | 4.89% | US#47/3,111 Sec#18/269 |
| Total Debt | $4M | US#2,897/3,111 Sec#225/269 |
| FCF | $-89M | US#2,573/3,111 Sec#143/269 |
| Cash | $242M | US#1,587/3,111 Sec#98/269 |
| Current Ratio | 24.76x | US#97/3,111 Sec#18/269 |
| Performance | ||
| 1Y Return | 161.65% | US#273/3,111 Sec#80/269 |
| 1M Return | -57.05% | US#3,107/3,111 Sec#267/269 |
| From 52W High | -58.47% | US#2,963/3,111 Sec#248/269 |
| 1Y MDD | -63.98% | US#2,809/3,111 Sec#228/269 |
| Trading | ||
| Volume | 3,489,524 shares | US#173/3,111 Sec#12/269 |
| Trading Value | $36M | US#927/3,111 Sec#55/269 |
| Per Share | ||
| EPS | $-1.52 | US—/3,111 Sec—/269 |
| BPS | $7.74 | US#1,968/3,111 Sec#91/269 |